FDA accepts application for generic version of Advair Diskus
The FDA has accepted Sandoz’s New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus...
List view / Grid view
News
Diabetes drug trial needs to widen participants to understand full impact
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds...
EMA issues guidance document in preparation for Brexit
The European Medicines Agency (EMA) and the European Commission have published guidance to help pharmaceutical companies prepare for the United Kingdom's withdrawal from the European Union.
EMA action plan supports SMEs as drivers of innovation
The European Medicines Agency (EMA) has published an action plan that aims to foster innovation and support small and medium-sized enterprises (SMEs) in the development of novel human and veterinary medicines.
AAM praises Supreme Court Ruling granting access to biosimilars
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
New industry forum to advance clinical trial participation
In 2018, industry leaders from pharma, biotech and clinical research organisations will advance the participation of patients in clinical trials...
EndPoint and SmartAction partner to automate Pharma/ Biotech services
SmartAction and EndPoint Technologies have formed a strategic partnership to expand the availability of AI-powered customer technology.
Lab Innovations – back for 2017!
Lab Innovations – the UK’s only dedicated showcase for laboratory technology, analytical and biotech equipment – returns for its sixth consecutive year on 1 & 2 November 2017 at the NEC, Birmingham...
Precision NanoSystems at the BIO International Convention 2017
A key session opens up the challenges of delivering personalized genetic medicines...
Valeant announces sale of iNova Pharmaceuticals for $930 million
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
BIA report shows UK on track to be world’s third global biotech cluster
A new report released by the UK BioIndustry Association (BIA) shows that the UK maintained its strong leadership position in European biotech funding last year and has the strongest pipeline in Europe for future drug development.
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
FDA approves BioMarin’s manufacturing facility in Cork, Ireland
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
Initial successes in treating a hitherto incurable liver disorder
Primary sclerosing cholangitis is a currently incurable liver disorder, primarily affecting younger adults aged between 30 and 40.
Is the finger-stick blood test necessary for type 2 diabetes treatment?
In the first large pragmatic trial of its kind in the United States, results from a study show that checking finger-stick blood sugars may not help diabetes patients who do not use insulin.
